Next Article in Journal
Humoral Immune Response of Thai Dogs after Oral Vaccination against Rabies with the SPBN GASGAS Vaccine Strain
Previous Article in Journal
Intranasal Delivery of a Chitosan-Hydrogel Vaccine Generates Nasal Tissue Resident Memory CD8+ T Cells That Are Protective against Influenza Virus Infection
Previous Article in Special Issue
Impact of Influenza on Pneumococcal Vaccine Effectiveness during Streptococcus pneumoniae Infection in Aged Murine Lung
Open AccessReview

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines

1
Department of Comparative Pathobiology, Purdue Institute for Immunology, Inflammation and Infectious Disease, Purdue University Center for Cancer Research, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA
2
Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
*
Authors to whom correspondence should be addressed.
Vaccines 2020, 8(4), 574; https://doi.org/10.3390/vaccines8040574
Received: 2 August 2020 / Revised: 6 September 2020 / Accepted: 17 September 2020 / Published: 1 October 2020
(This article belongs to the Special Issue Viral Imprinting and Vaccine Design of Influenza and Other Viruses)
Ever since the discovery of vaccines, many deadly diseases have been contained worldwide, ultimately culminating in the eradication of smallpox and polio, which represented significant medical achievements in human health. However, this does not account for the threat influenza poses on public health. The currently licensed seasonal influenza vaccines primarily confer excellent strain-specific protection. In addition to the seasonal influenza viruses, the emergence and spread of avian influenza pandemic viruses such as H5N1, H7N9, H7N7, and H9N2 to humans have highlighted the urgent need to adopt a new global preparedness for an influenza pandemic. It is vital to explore new strategies for the development of effective vaccines for pandemic and seasonal influenza viruses. The new vaccine approaches should provide durable and broad protection with the capability of large-scale vaccine production within a short time. The adenoviral (Ad) vector-based vaccine platform offers a robust egg-independent production system for manufacturing large numbers of influenza vaccines inexpensively in a short timeframe. In this review, we discuss the progress in the development of Ad vector-based influenza vaccines and their potential in designing a universal influenza vaccine. View Full-Text
Keywords: adenoviral vector; human adenoviral vector; nonhuman adenoviral vector; influenza vaccine; universal influenza vaccine adenoviral vector; human adenoviral vector; nonhuman adenoviral vector; influenza vaccine; universal influenza vaccine
Show Figures

Figure 1

MDPI and ACS Style

Sayedahmed, E.E.; Elkashif, A.; Alhashimi, M.; Sambhara, S.; Mittal, S.K. Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines. Vaccines 2020, 8, 574.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop